CB 2679d

Drug Profile

CB 2679d

Alternative Names: CB FIX; Factor IX - Catalyst Biosciences; FIX-NG; ISU 304

Latest Information Update: 15 Jul 2017

Price : $50

At a glance

  • Originator Catalyst Biosciences
  • Developer Catalyst Biosciences; ISU Abxis
  • Class Antihaemorrhagics; Blood coagulation factors; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Blood coagulation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haemophilia B

Most Recent Events

  • 28 Jun 2017 Research programme: second generation factor IX molecules - Catalyst Biosciences receives Orphan Drug status for Haemophilia B in European Union
  • 26 Jun 2017 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Haemophilia B released by Catalyst Biosciences
  • 03 Jun 2017 Phase-I/II clinical trials in Haemophilia B (In adolescents, In children, Treatment-experienced, In adults) in South Korea (IV) (NCT03186677)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top